Please ensure Javascript is enabled for purposes of website accessibility

Regeneron Says Its COVID-19 Combo Treatment Could Be Ready for People This Fall

By Cory Renauer – May 5, 2020 at 3:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Development of the company's coronavirus cocktail is progressing at top speed.

During Regeneron's (REGN -2.09%) earnings call on Tuesday, Chief Scientific Officer George Yancopoulos told analysts that the company planned to start human trials of REGN-COV2, the company's experimental COVID-19 treatment, in June. That means that if results from those studies are positive, the antibody cocktail could be available for use by the end of summer or fall. 

From Ebola to COVID-19 

Remdesivir, a recently approved COVID-19 treatment from Gilead Sciences (GILD -1.53%), and Regeneron's antibody cocktail both emerged from an Ebola study. While Gilead was ready to test its older antiviral candidate against COVID-19 right off the bat, Regeneron quickly developed new antibodies that specifically bind to the SARS-CoV-2 spike protein. 

Surgical mask close up.

Image source: Getty Images.

Gilead's remdesivir was shown to reduce the number of days critically ill COVID-19 patients spent hospitalized from 15 to 11, which isn't a very high bar for Regeneron's antibody cocktail to vault over.

Track record

In April, the FDA accepted an application from Regeneron for REGN-EB3 as an Ebola treatment, and it's largely expected to earn approval. The antibody cocktail outperformed other investigational antiviral drugs in the Ebola study by a mile, including remdesivir.

The REGN-COV2 program is using a multi-antibody approach that targets different parts of SARS-CoV-2. Regeneron used the same platform to rapidly develop its coronavirus antiviral as it used to develop REGN-EB3 for Ebola. 

In April, Regeneron moved its REGN-COV2 antibodies into clinical-scale production and expects to have hundreds of thousands of doses available by the end of August. While Regeneron is going to develop REGN-EB3 as a treatment for people who have severe cases of COVID-19, it could also be used to prevent new infections.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$690.70 (-2.09%) $-14.72
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.95 (-1.53%) $0.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.